

# Leukaemia Section

## Short Communication

### t(17;17)(q21;q24), del(17)(q21q24)

Jean-Loup Huret

Genetics, Dept Medical Information, University of Poitiers, CHU Poitiers Hospital, F-86021 Poitiers, France (JLH)

Published in Atlas Database: August 2011

Online updated version : <http://AtlasGeneticsOncology.org/Anomalies/t1717q21q24ID1497.html>

DOI: 10.4267/2042/47271

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 2.0 France Licence.  
© 2012 Atlas of Genetics and Cytogenetics in Oncology and Haematology

## Clinics and pathology

### Disease

Acute myeloid leukaemia, M3 subtype (M3-AML)

### Epidemiology

Only one case to date, a 66-year-old male patient (Catalano et al., 2007).

### Cytology

Auer rods and fagot cells were absent.

### Evolution

Complete remission was obtained with ATRA, and the patient remains healthy 2 years after the diagnosis.

## Cytogenetics

### Cytogenetics morphological

Cryptic deletion, FISH studies are needed to uncover the rearrangement.

## Genes involved and proteins

### RARA

#### Location

17q21.1

#### Protein

Contains Zn fingers and a ligand binding region. Receptor for retinoic acid. Forms heterodimers with

RXR. At the DNA level, binds to retinoic acid response elements (RARE). Ligand-dependent transcription factor specifically involved in hematopoietic cells differentiation and maturation.

### PRKAR1A

#### Location

17q24.2

#### Protein

Contains two tandem cAMP-binding domains. Forms heterotetramers with PRKACA (protein kinase, cAMP-dependent, catalytic, alpha), also called PKA. Interacts with RARA, and regulates RARA transcriptional activity.

## Result of the chromosomal anomaly


### Hybrid gene

#### Description

5' PRKAR1A - 3' RARA. When we look closely to the DNA sequences at the fusion breakpoints, they correspond to the very end of exon 1 in PRKAR1A (AGAGGTTGGAGAAG) and the very beginning of exon 2 in RARA (ATTGAGACCCAGAGCAGCAGT, see sequences in Ensembl), although they were described in exon 2 and exon 3 in the first and only report of this rearrangement (Catalano et al., 2007).

### Fusion protein

See figure 5' PRKAR1A - 3' RARA.



Dimerization domain from PRKAR1A fused to  
Zn fingers and Ligand binding region from RARA

Note from JLH: according to the DNA sequences at the fusion breakpoints, as noted by the authors, and to those described in Ensembl, it appears that breaks occurred at the very end of exon 1 in PRKAR1A (AGAGTTGGAGAAG) and at the very beginning of exon 2 in RARA (ATTGAGACCCAGAGCAGCAGT), although they were described in exon 2 and exon 3.

## 5' PRKAR1A - 3' RARA

Jean Loup Huret 2012

### Description

The fusion protein contains the dimerization domain from PRKAR1A fused to the Zn fingers and ligand binding regions from RARA.

### References

Solberg R, Sandberg M, Natarajan V, Torjesen PA, Hansson V, Jahnsen T, Taskén K. The human gene for the regulatory subunit RI alpha of cyclic adenosine 3', 5'-monophosphate-dependent protein kinase: two distinct promoters provide

differential regulation of alternately spliced messenger ribonucleic acids. *Endocrinology*. 1997 Jan;138(1):169-81

Catalano A, Dawson MA, Somana K, Opat S, Schwarzer A, Campbell LJ, Iland H. The PRKAR1A gene is fused to RARA in a new variant acute promyelocytic leukemia. *Blood*. 2007 Dec 1;110(12):4073-6

*This article should be referenced as such:*

Huret JL. t(17;17)(q21;q24), del(17)(q21q24). *Atlas Genet Cytogenet Oncol Haematol*. 2012; 16(1):49-50.